Pharsight

1. Drug name - ABILIFY

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9359302	OTSUKA	Low hygroscopic aripiprazole drug substance and processes for the preparation thereof	Sep, 2022 (8 days ago)
US8642760	OTSUKA	Low hygroscopic aripiprazole drug substance and processes for the preparation thereof	Sep, 2022 (8 days ago)
US8580796	OTSUKA	Low hygroscopic aripiprazole drug substance and processes for the preparation thereof	Sep, 2022 (8 days ago)
CN103288727A	OTSUKA	Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
CN1817882A	OTSUKA	Low Hygroscopic Aripiprazole Medicine And Preparation Method Thereof	Sep, 2022 (8 days ago)
CN103288727B	OTSUKA	Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
CN1817882B	OTSUKA	Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
EP1419776B1	OTSUKA	Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
EP1927355B1	OTSUKA	Low Hygroscopic Aripiprazole (Crystal F) Drug Substance And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
EP1927357A3	OTSUKA	Low Hygroscopic Aripiprazole (Crystal E) Drug Substance And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
EP1419776A2	OTSUKA	Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
EP1925308A1	OTSUKA	Pharmaceutical Solid Oral Aripiprazole Preparation And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
EP1419776A3	OTSUKA	Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
EP1927356A1	OTSUKA	Low Hygroscopic Aripiprazole (Crystal D) Drug Substance And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
EP1419776B2	OTSUKA	Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
EP1927355A1	OTSUKA	Low Hygroscopic Aripiprazole (Crystal F) Drug Substance And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
EP1927356B1	OTSUKA	Low Hygroscopic Aripiprazole (Crystal D) Drug Substance And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
EP1927357A2	OTSUKA	Low Hygroscopic Aripiprazole (Crystal E) Drug Substance And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
EP1419776A8	OTSUKA	Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
EP1419776A9	OTSUKA	Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
EP1925308B1	OTSUKA	Pharmaceutical Solid Oral Aripiprazole Preparation And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
EP1927357B1	OTSUKA	Low Hygroscopic Aripiprazole (Crystal E) Drug Substance And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6977257 (Pediatric)	OTSUKA	Aripiprazole oral solution	Oct, 2022 (20 days from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

Strength	Dosage	Availability
10MG	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued
15MG	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued
20MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued
30MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued

2. Drug name - ABILIFY MAINTENA KIT

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8993761	OTSUKA PHARM CO LTD	Low hygroscopic aripiprazole drug substance and processes for the preparation thereof	Sep, 2022 (8 days ago)
CN103288727A	OTSUKA PHARM CO LTD	Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
CN1817882A	OTSUKA PHARM CO LTD	Low Hygroscopic Aripiprazole Medicine And Preparation Method Thereof	Sep, 2022 (8 days ago)
CN103288727B	OTSUKA PHARM CO LTD	Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
CN1817882B	OTSUKA PHARM CO LTD	Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
EP1419776B1	OTSUKA PHARM CO LTD	Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
EP1927355B1	OTSUKA PHARM CO LTD	Low Hygroscopic Aripiprazole (Crystal F) Drug Substance And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
EP1927357A3	OTSUKA PHARM CO LTD	Low Hygroscopic Aripiprazole (Crystal E) Drug Substance And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
EP1419776A2	OTSUKA PHARM CO LTD	Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
EP1925308A1	OTSUKA PHARM CO LTD	Pharmaceutical Solid Oral Aripiprazole Preparation And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
EP1419776A3	OTSUKA PHARM CO LTD	Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
EP1927356A1	OTSUKA PHARM CO LTD	Low Hygroscopic Aripiprazole (Crystal D) Drug Substance And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
EP1419776B2	OTSUKA PHARM CO LTD	Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
EP1927355A1	OTSUKA PHARM CO LTD	Low Hygroscopic Aripiprazole (Crystal F) Drug Substance And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
EP1927356B1	OTSUKA PHARM CO LTD	Low Hygroscopic Aripiprazole (Crystal D) Drug Substance And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
EP1927357A2	OTSUKA PHARM CO LTD	Low Hygroscopic Aripiprazole (Crystal E) Drug Substance And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
EP1419776A8	OTSUKA PHARM CO LTD	Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
EP1419776A9	OTSUKA PHARM CO LTD	Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
EP1925308B1	OTSUKA PHARM CO LTD	Pharmaceutical Solid Oral Aripiprazole Preparation And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
EP1927357B1	OTSUKA PHARM CO LTD	Low Hygroscopic Aripiprazole (Crystal E) Drug Substance And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)

Drugs and Companies using ARIPIPRAZOLE ingredient

Treatment: NA

Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

Strength	Dosage	Availability
300MG/VIAL	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
300MG	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
400MG/VIAL	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
400MG	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription

3. Drug name - ABILIFY MYCITE KIT

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9359302	OTSUKA	Low hygroscopic aripiprazole drug substance and processes for the preparation thereof	Sep, 2022 (8 days ago)
US8642760	OTSUKA	Low hygroscopic aripiprazole drug substance and processes for the preparation thereof	Sep, 2022 (8 days ago)
US8580796	OTSUKA	Low hygroscopic aripiprazole drug substance and processes for the preparation thereof	Sep, 2022 (8 days ago)
CN103288727A	OTSUKA	Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
CN1817882A	OTSUKA	Low Hygroscopic Aripiprazole Medicine And Preparation Method Thereof	Sep, 2022 (8 days ago)
CN103288727B	OTSUKA	Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
CN1817882B	OTSUKA	Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
EP1419776B1	OTSUKA	Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
EP1927355B1	OTSUKA	Low Hygroscopic Aripiprazole (Crystal F) Drug Substance And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
EP1927357A3	OTSUKA	Low Hygroscopic Aripiprazole (Crystal E) Drug Substance And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
EP1419776A2	OTSUKA	Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
EP1925308A1	OTSUKA	Pharmaceutical Solid Oral Aripiprazole Preparation And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
EP1419776A3	OTSUKA	Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
EP1927356A1	OTSUKA	Low Hygroscopic Aripiprazole (Crystal D) Drug Substance And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
EP1419776B2	OTSUKA	Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
EP1927355A1	OTSUKA	Low Hygroscopic Aripiprazole (Crystal F) Drug Substance And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
EP1927356B1	OTSUKA	Low Hygroscopic Aripiprazole (Crystal D) Drug Substance And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
EP1927357A2	OTSUKA	Low Hygroscopic Aripiprazole (Crystal E) Drug Substance And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
EP1419776A8	OTSUKA	Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
EP1419776A9	OTSUKA	Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
EP1925308B1	OTSUKA	Pharmaceutical Solid Oral Aripiprazole Preparation And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)
EP1927357B1	OTSUKA	Low Hygroscopic Aripiprazole (Crystal E) Drug Substance And Processes For The Preparation Thereof	Sep, 2022 (8 days ago)

Drugs and Companies using ARIPIPRAZOLE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
2MG	TABLET;ORAL	Prescription
5MG	TABLET;ORAL	Prescription
10MG	TABLET;ORAL	Prescription
15MG	TABLET;ORAL	Prescription
20MG	TABLET;ORAL	Prescription
30MG	TABLET;ORAL	Prescription

4. Drug name - ADDYI

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7420057	SPROUT PHARMS	Stable polymorph of flibanserin	Aug, 2022 (2 months ago)
IN226632B	SPROUT PHARMS	Crystalline Polymorph A (Form A) Of Flibanserin 1 And Process For Preparing The Same	Jul, 2022 (2 months ago)
IN200302139P1	SPROUT PHARMS	Crystalline Polymorph A (Form A) Of Flibanserin 1 And Process For Preparing The Same	Jul, 2022 (2 months ago)
EP1414816B1	SPROUT PHARMS	Stable Polymorph Of Flibanserin, Technical Process For Its Preparation And The Use Thereof For Preparing Medicaments	Jul, 2022 (2 months ago)
EP1414816A1	SPROUT PHARMS	Stable Polymorph Of Flibanserin, Technical Process For Its Preparation And The Use Thereof For Preparing Medicaments	Jul, 2022 (2 months ago)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9468639	SPROUT PHARMS	Treating sexual desire disorders with flibanserin	Oct, 2022 (12 days from now)

Drugs and Companies using FLIBANSERIN ingredient

Treatment: Use of flibanserin or a pharmaceutically acceptable acid addition salt thereof to treat hypoactive sexual desire disorder (hsdd)

Dosage: TABLET;ORAL

Strength	Dosage	Availability
100MG	TABLET;ORAL	Prescription

5. Drug name - AMITIZA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8097653	SUCAMPO PHARMA LLC	Dosage unit comprising a prostaglandin analog for treating constipation	Nov, 2022 (a month from now)
US8389542	SUCAMPO PHARMA LLC	Dosage unit comprising a prostaglandin analog for treating constipation	Nov, 2022 (a month from now)
US6982283	SUCAMPO PHARMA LLC	Method for treating drug-induced constipation	Dec, 2022 (2 months from now)

Drugs and Companies using LUBIPROSTONE ingredient

Treatment: Method for relieving constipation in a patient with opioid-induced constipation that comprises administering to the patient a dosage unit comprising(i)24microg+/- 10% of a drug substance and (ii) a pharmaceutically suitable excipient; method for relieving constipation in a human patient that comprises administering to the patient a dosage unit comprising (i) 24mcg+/- 10% of a drug substance and (ii) a pharmaceutically suitable excipient; Use in relieving or preventing constipation in a human patient with a dosage unit comprising 24microg+/- 10% of a drug substance and a pharmaceutically suitable excipient; use in relieving or preventing constipation in a patient with opioid-induced constipation with a dosage unit comprising 24microg +/- 10% of a drug substance and a pharmaceutically suitable excipient; Method for treating opioid-induced constipation

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
8MCG	CAPSULE;ORAL	Prescription
24MCG	CAPSULE;ORAL	Prescription

6. Drug name - AMLODIPINE BESYLATE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6828339	SYNTHON PHARMS	Amlodipine salt forms and processes for preparing them	Nov, 2022 (a month from now)

Drugs and Companies using AMLODIPINE BESYLATE ingredient

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

Strength	Dosage	Availability
EQ 2.5MG BASE	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued
EQ 5MG BASE	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued
EQ 10MG BASE	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued

7. Drug name - ANJESO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8512727	BAUDAX	Nanoparticulate meloxicam formulations	Dec, 2022 (2 months from now)

Drugs and Companies using MELOXICAM ingredient

Treatment: Management of moderate-to-severe pain by intravenous injection

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
30MG/ML (30MG/ML)	SOLUTION;INTRAVENOUS	Prescription

8. Drug name - AVANDAMET

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8236345	SB PHARMCO	Composition and use	Oct, 2022 (3 days from now)

Drugs and Companies using METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
1GM;EQ 2MG BASE	TABLET;ORAL	Discontinued
1GM;EQ 4MG BASE	TABLET;ORAL	Discontinued
500MG;EQ 1MG BASE	TABLET;ORAL	Discontinued
500MG;EQ 2MG BASE	TABLET;ORAL	Discontinued
500MG;EQ 4MG BASE	TABLET;ORAL	Discontinued

9. Drug name - BANZEL

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6740669	EISAI INC	Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic	Nov, 2022 (a month from now)
EP994863B1	EISAI INC	Crystal Modification Of 1-(2,6-Difluorobenzyl)-1H-1,2,3-Triazole-4-Carboxamide And Its Use As Antiepileptic	Jan, 2022 (8 months ago)
EP994863A1	EISAI INC	Crystal Modification Of 1-(2,6-Difluorobenzyl)-1H-1,2,3-Triazole-4-Carboxamide And Its Use As Antiepileptic	Jan, 2022 (8 months ago)

Drugs and Companies using RUFINAMIDE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
100MG	TABLET;ORAL	Discontinued
200MG	TABLET;ORAL	Prescription
400MG	TABLET;ORAL	Prescription

10. Drug name - BEYAZ

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6441168	BAYER HLTHCARE	Stable crystalline salts of 5-methyltetrahydrofolic acid	Jul, 2022 (2 months ago)

Drugs and Companies using DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
3MG,N/A;0.02MG,N/A;0.451MG,0.451MG	TABLET;ORAL	Prescription

11. Drug name - BYDUREON

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6824822	ASTRAZENECA AB	Residual solvent extraction method and microparticles produced thereby	Oct, 2022 (5 days from now)

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Treatment: NA

Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

Strength	Dosage	Availability
2MG/VIAL	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	Discontinued
2MG	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	Discontinued

12. Drug name - BYDUREON BCISE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6824822	ASTRAZENECA AB	Residual solvent extraction method and microparticles produced thereby	Oct, 2022 (5 days from now)

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

Strength	Dosage	Availability
2MG/0.85ML (2MG/0.85ML)	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	Prescription

13. Drug name - BYLVAY

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7132416	ALBIREO	Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (IBAT) inhibotory activity for the treatment hyperlipidaemia	Sep, 2022 (28 days ago)
IN200400539P1	ALBIREO	Benzothiazepine And Benzothiadiazepine Derivatives With Lleal Bile Acid Transport (Ibat) Inhibitory Activity For The Treatment Of Hyperlipidaemia	Sep, 2022 (28 days ago)
IN248635B	ALBIREO	Benzothiazepine And Benzothiadiazepine Derivatives With Lleal Bile Acid Transport (Ibat) Inhibitory Activity For The Treatment Of Hyperlipidaemia	Sep, 2022 (28 days ago)
EP1427423A1	ALBIREO	Benzothiazepine And Benzothiadiazepine Derivatives With Ileal Bile Acid Transport (Ibat) Inhibitory Activity For The Treatment Hyperlipidaemia	Sep, 2022 (28 days ago)
EP1427423B9	ALBIREO	Benzothiazepine And Benzothiadiazepine Derivatives With Ileal Bile Acid Transport (Ibat) Inhibitory Activity For The Treatment Hyperlipidaemia	Sep, 2022 (28 days ago)
EP1427423B1	ALBIREO	Benzothiazepine And Benzothiadiazepine Derivatives With Ileal Bile Acid Transport (Ibat) Inhibitory Activity For The Treatment Hyperlipidaemia	Sep, 2022 (28 days ago)

Drugs and Companies using ODEVIXIBAT ingredient

Treatment: NA

Dosage: CAPSULE, PELLETS;ORAL; CAPSULE;ORAL

Strength	Dosage	Availability
0.2MG	CAPSULE, PELLETS;ORAL	Prescription
0.6MG	CAPSULE, PELLETS;ORAL	Prescription
0.4MG	CAPSULE;ORAL	Prescription
1.2MG	CAPSULE;ORAL	Prescription

14. Drug name - CAPRELSA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE42353	GENZYME CORP	Quinazoline derivatives and pharmaceutical compositions containing them	Jun, 2022 (3 months ago)

Drugs and Companies using VANDETANIB ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
100MG	TABLET;ORAL	Prescription
300MG	TABLET;ORAL	Prescription

15. Drug name - CERDELGA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6916802	GENZYME CORP	Amino ceramide-like compounds and therapeutic methods of use	Apr, 2022 (5 months ago)

Drugs and Companies using ELIGLUSTAT TARTRATE ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 84MG BASE	CAPSULE;ORAL	Prescription

16. Drug name - CHANTIX

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6890927	PF PRISM CV	Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof	May, 2022 (4 months ago)
US7265119	PF PRISM CV	Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof	Aug, 2022 (2 months ago)
CN100370987C	PF PRISM CV	5, 8, 14-Aminosteroid, Triaza-Tetracyclo [10.3.1.0. 2.11. 0. 4.9]--2 (11), 3, 5, 7, 9, - Pentaene-Tartrate	Apr, 2022 (5 months ago)
CN1509174A	PF PRISM CV	5, 8, 14-Aminosteroid, Triaza-Tetracyclo [10.3.1.0	Apr, 2022 (5 months ago)
IN204091B	PF PRISM CV	Compound Of 5,8,14-Triazatracyclo[10.3.1.02.11.04.9]-Hexadeca-2(11),3,5,7,9-Pentaene	Apr, 2022 (5 months ago)
IN200300863P3	PF PRISM CV	Compound Of 5,8,14-Triazatracyclo[10.3.1.02.11.04.9]-Hexadeca-2(11),3,5,7,9-Pentaene	Apr, 2022 (5 months ago)
EP1392307A1	PF PRISM CV	Tartrate Salts Of 5,8,14-Triazatetracyclo[10.3.1.02,11.04,9]-Hexadeca-2(11),3,5,7,9-Pentaene	Apr, 2022 (5 months ago)
EP1392307B1	PF PRISM CV	Tartrate Salts Of 5,8,14-Triazatetracyclo¬10.3.1.02,11.04,9-Hexadeca-2(11),3,5,7,9-Pentaene	Apr, 2022 (5 months ago)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6890927 (Pediatric)	PF PRISM CV	Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof	Nov, 2022 (a month from now)

Drugs and Companies using VARENICLINE TARTRATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 0.5MG BASE	TABLET;ORAL	Prescription
EQ 1MG BASE	TABLET;ORAL	Prescription

17. Drug name - COMBIGAN

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7642258	ALLERGAN	Combination of brimonidine and timolol for topical ophthalmic use	Apr, 2022 (5 months ago)
CN112219061A	ALLERGAN	Suspension Type Vertical Decoration Light Guide Lamp With Sound Suppression	Jan, 2022 (8 months ago)

Drugs and Companies using BRIMONIDINE TARTRATE; TIMOLOL MALEATE ingredient

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

Strength	Dosage	Availability
0.2%;EQ 0.5% BASE	SOLUTION/DROPS;OPHTHALMIC	Prescription

18. Drug name - DORYX

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6958161	MAYNE PHARMA	Modified release coated drug preparation	Dec, 2022 (2 months from now)

Drugs and Companies using DOXYCYCLINE HYCLATE ingredient

Treatment: To treat or prevent infections caused by susceptible bacteria using delayed-release tablets consisting of doxycycline hyclate coated pellets in a tablet

Dosage: TABLET, DELAYED RELEASE;ORAL

Strength	Dosage	Availability
EQ 50MG BASE	TABLET, DELAYED RELEASE;ORAL	Prescription
EQ 75MG BASE	TABLET, DELAYED RELEASE;ORAL	Prescription
EQ 80MG BASE	TABLET, DELAYED RELEASE;ORAL	Prescription
EQ 100MG BASE	TABLET, DELAYED RELEASE;ORAL	Prescription
EQ 150MG BASE	TABLET, DELAYED RELEASE;ORAL	Prescription
EQ 200MG BASE	TABLET, DELAYED RELEASE;ORAL	Prescription
EQ 60MG BASE	TABLET, DELAYED RELEASE;ORAL	Discontinued
EQ 120MG BASE	TABLET, DELAYED RELEASE;ORAL	Prescription

19. Drug name - DUTREBIS

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7217713	MERCK SHARP DOHME	N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase	Oct, 2022 (17 days from now)
US7435734	MERCK SHARP DOHME	N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase	Oct, 2022 (17 days from now)

Drugs and Companies using LAMIVUDINE; RALTEGRAVIR POTASSIUM ingredient

Treatment: Treatment of hiv-1 infection

Dosage: TABLET;ORAL

Strength	Dosage	Availability
150MG;EQ 300MG BASE	TABLET;ORAL	Discontinued

20. Drug name - EPIDIOLEX

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10195159	GW RES LTD	Processes and apparatus for extraction of active substances and enriched extracts from natural products	May, 2022 (4 months ago)
EP1385595A2	GW RES LTD	Processes For Preparing A Cannabinoid-Rich Extract From Cannabis Plant Material	May, 2022 (4 months ago)
EP1385595B1	GW RES LTD	Processes For Preparing A Cannabinoid-Rich Extract From Cannabis Plant Material	May, 2022 (4 months ago)

Drugs and Companies using CANNABIDIOL ingredient

Treatment: NA

Dosage: SOLUTION;ORAL

Strength	Dosage	Availability
100MG/ML	SOLUTION;ORAL	Prescription

21. Drug name - EPIDUO

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8241649	GALDERMA LABS LP	Dermatological/cosmetic gels comprising at least one retinoid and/or retinoid salt and benzoyl peroxide	Dec, 2022 (2 months from now)
US8936800	GALDERMA LABS LP	Gel composition for treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt	Dec, 2022 (2 months from now)
US8105618	GALDERMA LABS LP	Dermatological/cosmetic gels comprising at least one retinoid and/or retinoid salt and benzoyl peroxide	Dec, 2022 (2 months from now)
US8809305	GALDERMA LABS LP	Administration of adapalene and benzoyl peroxide for the long-term treatment of acne vulgaris	Dec, 2022 (2 months from now)

Drugs and Companies using ADAPALENE; BENZOYL PEROXIDE ingredient

Treatment: Treatment of acne

Dosage: GEL;TOPICAL

Strength	Dosage	Availability
0.1%;2.5%	GEL;TOPICAL	Prescription

22. Drug name - EPIDUO FORTE

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8785420	GALDERMA LABS	Combination/association of adapalene and benzoyl peroxide for treating acne lesions	Dec, 2022 (2 months from now)
US8936800	GALDERMA LABS	Gel composition for treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt	Dec, 2022 (2 months from now)
US8445543	GALDERMA LABS	Combinations of adapalene and benzoyl peroxide for treating acne lesions	Dec, 2022 (2 months from now)
US8809305	GALDERMA LABS	Administration of adapalene and benzoyl peroxide for the long-term treatment of acne vulgaris	Dec, 2022 (2 months from now)
US9814690	GALDERMA LABS	Gel composition for treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt	Dec, 2022 (2 months from now)

Drugs and Companies using ADAPALENE; BENZOYL PEROXIDE ingredient

Treatment: Treatment of acne

Dosage: GEL;TOPICAL

Strength	Dosage	Availability
0.3%;2.5%	GEL;TOPICAL	Prescription

23. Drug name - FOLOTYN

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6028071	ACROTECH	Purified compositions of 10-propargyl-10-deazaaminopterin and methods of using same in the treatment of tumors	Jul, 2022 (2 months ago)

Drugs and Companies using PRALATREXATE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
20MG/ML (20MG/ML)	SOLUTION;INTRAVENOUS	Prescription
40MG/2ML (20MG/ML)	SOLUTION;INTRAVENOUS	Prescription

24. Drug name - FUSILEV

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6500829	ACROTECH	Substantially pure diastereoisomers of tetrahydrofolate derivatives	Mar, 2022 (6 months ago)

Drugs and Companies using LEVOLEUCOVORIN CALCIUM ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
EQ 50MG BASE/VIAL	POWDER;INTRAVENOUS	Prescription
EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	SOLUTION;INTRAVENOUS	Discontinued
EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	SOLUTION;INTRAVENOUS	Discontinued

25. Drug name - FYCOMPA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6949571	EISAI INC	1,2-dihydropyridine compounds, process for preparation of the same and use thereof	Jun, 2022 (3 months ago)

Drugs and Companies using PERAMPANEL ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
2MG	TABLET;ORAL	Prescription
4MG	TABLET;ORAL	Prescription
6MG	TABLET;ORAL	Prescription
8MG	TABLET;ORAL	Prescription
10MG	TABLET;ORAL	Prescription
12MG	TABLET;ORAL	Prescription

26. Drug name - GIVLAARI

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8546143	ALNYLAM PHARMS INC	Compositions and methods for inhibiting expression of a target gene	Jan, 2022 (8 months ago)
IN203882B	ALNYLAM PHARMS INC	Method For Inhibiting The Expression Of A Targe Gene	Jan, 2022 (8 months ago)
IN213846B	ALNYLAM PHARMS INC	Method For Inhibiting The Expression Of A Target Gene	Jan, 2022 (8 months ago)
IN200300572P3	ALNYLAM PHARMS INC	Method For Inhibiting The Expression Of A Target Gene	Jan, 2022 (8 months ago)
IN200300537P3	ALNYLAM PHARMS INC	Method For Inhibiting The Expression Of A Target Gene	Jan, 2022 (8 months ago)
EP1352061B1	ALNYLAM PHARMS INC	Method For Inhibiting The Expression Of A Target Gene	Jan, 2022 (8 months ago)
EP1352061B9	ALNYLAM PHARMS INC	Method For Inhibiting The Expression Of A Target Gene	Jan, 2022 (8 months ago)
EP1352061A2	ALNYLAM PHARMS INC	Method For Inhibiting The Expression Of A Target Gene	Jan, 2022 (8 months ago)
EP2213736A3	ALNYLAM PHARMS INC	Method For Inhibiting The Expression Of A Target Gene And Medicine For Treating A Tumour Illness	Jan, 2022 (8 months ago)
EP2213736B1	ALNYLAM PHARMS INC	Method For Inhibiting The Expression Of A Target Gene And Medicine For Treating A Tumour Illness	Jan, 2022 (8 months ago)
EP2213736A2	ALNYLAM PHARMS INC	Method For Inhibiting The Expression Of A Target Gene And Medicine For Treating A Tumour Illness	Jan, 2022 (8 months ago)

Drugs and Companies using GIVOSIRAN SODIUM ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
EQ 189MG BASE/ML (EQ 189MG BASE/ML)	SOLUTION;SUBCUTANEOUS	Prescription

27. Drug name - GRALISE

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8252332	ALMATICA	Gastric retained gabapentin dosage form	Oct, 2022 (21 days from now)
US8192756	ALMATICA	Gastric retained gabapentin dosage form	Oct, 2022 (21 days from now)
US8333992	ALMATICA	Gastric retained gabapentin dosage form	Oct, 2022 (21 days from now)
US7731989	ALMATICA	Gastric retained gabapentin dosage form	Oct, 2022 (21 days from now)

Drugs and Companies using GABAPENTIN ingredient

Treatment: Treatment with gabapentin, including treatment of neuropathic pain, including neuropathic pain associated with postherpetic neuralgia

Dosage: TABLET;ORAL

Strength	Dosage	Availability
300MG	TABLET;ORAL	Prescription
600MG	TABLET;ORAL	Prescription

28. Drug name - HALFLYTELY

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7291324	BRAINTREE	Method of bowel cleansing	Oct, 2022 (18 days from now)

Drugs and Companies using BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE ingredient

Treatment: Gastrointestinal lavage indicated for cleansing of the colon as a preparation for colonoscopy in adults

Dosage: FOR SOLUTION, TABLET, DELAYED RELEASE;ORAL

Strength	Dosage	Availability
5MG,N/A;N/A,210GM;N/A,0.74GM;N/A,2.86GM;N/A,5.6GM	FOR SOLUTION, TABLET, DELAYED RELEASE;ORAL	Discontinued

29. Drug name - HETLIOZ

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US5856529	VANDA PHARMS INC	Benzofuran and dihydrobenzofuran melatonergic agents	Dec, 2022 (2 months from now)

Drugs and Companies using TASIMELTEON ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
20MG	CAPSULE;ORAL	Prescription

30. Drug name - HETLIOZ LQ

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US5856529	VANDA PHARMS INC	Benzofuran and dihydrobenzofuran melatonergic agents	Dec, 2022 (2 months from now)

Drugs and Companies using TASIMELTEON ingredient

Treatment: NA

Dosage: SUSPENSION;ORAL

Strength	Dosage	Availability
4MG/ML	SUSPENSION;ORAL	Prescription

31. Drug name - HORIZANT

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8048917	ARBOR PHARMS LLC	Prodrugs of GABA analogs, compositions and uses thereof	Nov, 2022 (a month from now)
CN101434572A	ARBOR PHARMS LLC	Prodrug Of Gaba Analogue, Composition And Application Thereof	Jun, 2022 (3 months ago)
CN101434572B	ARBOR PHARMS LLC	Prodrug Of Gaba Analogue, Composition And Application Thereof	Jun, 2022 (3 months ago)
EP1404324B1	ARBOR PHARMS LLC	Prodrugs Of Gaba Analogs, Compositions And Uses Thereof	Jun, 2022 (3 months ago)
EP1404324A4	ARBOR PHARMS LLC	Prodrugs Of Gaba Analogs, Compositions And Uses Thereof	Jun, 2022 (3 months ago)
EP1404324B2	ARBOR PHARMS LLC	Prodrugs Of Gaba Analogs, Compositions And Uses Thereof	Jun, 2022 (3 months ago)
EP1404324A2	ARBOR PHARMS LLC	Prodrugs Of Gaba Analogs, Compositions And Uses Thereof	Jun, 2022 (3 months ago)
EP1902714B1	ARBOR PHARMS LLC	Prodrugs Of Gaba Analogs, Compositions And Uses Thereof	Jun, 2022 (3 months ago)
EP1902714A1	ARBOR PHARMS LLC	Prodrugs Of Gaba Analogs, Compositions And Uses Thereof	Jun, 2022 (3 months ago)

Drugs and Companies using GABAPENTIN ENACARBIL ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
300MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
600MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

32. Drug name - INBRIJA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7384649	ACORDA	Particulate compositions for pulmonary delivery	Nov, 2022 (a month from now)

Drugs and Companies using LEVODOPA ingredient

Treatment: NA

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
42MG	POWDER;INHALATION	Prescription

33. Drug name - ISENTRESS

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7435734	MERCK SHARP DOHME	N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase	Oct, 2022 (17 days from now)
US7217713	MERCK SHARP DOHME	N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase	Oct, 2022 (17 days from now)

Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 400MG BASE	TABLET;ORAL	Prescription
EQ 600MG BASE	TABLET;ORAL	Prescription

34. Drug name - JANUMET

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6699871	MERCK SHARP DOHME	Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes	Jul, 2022 (2 months ago)
CN1524082A	MERCK SHARP DOHME	As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prophylaxis Of Diabetes Of -Amino Tetrahydro-Imidazo (1, 2-A) Pyrazines And Triazolo [4, 2,3-A) Pyrazine	Jul, 2022 (2 months ago)
CN1290848C	MERCK SHARP DOHME	As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prophylaxis Of Diabetes Of -Amino Tetrahydro-Imidazo (1, 2-A) Pyrazines And Triazolo [4, 2,3-A) Pyrazine	Jul, 2022 (2 months ago)
IN200400026P4	MERCK SHARP DOHME	Beta-Amino Heterocyclic Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes	Jul, 2022 (2 months ago)
IN209816B	MERCK SHARP DOHME	Beta-Amino Heterocyclic Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes	Jul, 2022 (2 months ago)
EP2292232B1	MERCK SHARP DOHME	Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines For Use In The Treatment Of Diabetes Type Ii	Jul, 2022 (2 months ago)
EP1625847B1	MERCK SHARP DOHME	Medical Use Of A Tetrahydrotriazolo[4,3-A]Pyrazine	Jul, 2022 (2 months ago)
EP1625847A1	MERCK SHARP DOHME	Medical Use Of A Tetrahydrotriazolo[4,3-A]Pyrazine	Jul, 2022 (2 months ago)
EP2292232A1	MERCK SHARP DOHME	Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines For Use In The Treatment Of Diabetes Type Ii	Jul, 2022 (2 months ago)

Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
1GM;EQ 50MG BASE	TABLET;ORAL	Prescription
500MG;EQ 50MG BASE	TABLET;ORAL	Prescription

35. Drug name - JANUMET XR

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6699871	MERCK SHARP DOHME	Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes	Jul, 2022 (2 months ago)
CN1524082A	MERCK SHARP DOHME	As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prophylaxis Of Diabetes Of -Amino Tetrahydro-Imidazo (1, 2-A) Pyrazines And Triazolo [4, 2,3-A) Pyrazine	Jul, 2022 (2 months ago)
CN1290848C	MERCK SHARP DOHME	As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prophylaxis Of Diabetes Of -Amino Tetrahydro-Imidazo (1, 2-A) Pyrazines And Triazolo [4, 2,3-A) Pyrazine	Jul, 2022 (2 months ago)
IN200400026P4	MERCK SHARP DOHME	Beta-Amino Heterocyclic Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes	Jul, 2022 (2 months ago)
IN209816B	MERCK SHARP DOHME	Beta-Amino Heterocyclic Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes	Jul, 2022 (2 months ago)
EP2292232B1	MERCK SHARP DOHME	Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines For Use In The Treatment Of Diabetes Type Ii	Jul, 2022 (2 months ago)
EP1625847B1	MERCK SHARP DOHME	Medical Use Of A Tetrahydrotriazolo[4,3-A]Pyrazine	Jul, 2022 (2 months ago)
EP1625847A1	MERCK SHARP DOHME	Medical Use Of A Tetrahydrotriazolo[4,3-A]Pyrazine	Jul, 2022 (2 months ago)
EP2292232A1	MERCK SHARP DOHME	Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines For Use In The Treatment Of Diabetes Type Ii	Jul, 2022 (2 months ago)

Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
1GM;EQ 50MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
1GM;EQ 100MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
500MG;EQ 50MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription

36. Drug name - JANUVIA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6699871	MERCK SHARP DOHME	Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes	Jul, 2022 (2 months ago)
CN1524082A	MERCK SHARP DOHME	As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prophylaxis Of Diabetes Of -Amino Tetrahydro-Imidazo (1, 2-A) Pyrazines And Triazolo [4, 2,3-A) Pyrazine	Jul, 2022 (2 months ago)
CN1290848C	MERCK SHARP DOHME	As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prophylaxis Of Diabetes Of -Amino Tetrahydro-Imidazo (1, 2-A) Pyrazines And Triazolo [4, 2,3-A) Pyrazine	Jul, 2022 (2 months ago)
IN200400026P4	MERCK SHARP DOHME	Beta-Amino Heterocyclic Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes	Jul, 2022 (2 months ago)
IN209816B	MERCK SHARP DOHME	Beta-Amino Heterocyclic Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes	Jul, 2022 (2 months ago)
EP2292232B1	MERCK SHARP DOHME	Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines For Use In The Treatment Of Diabetes Type Ii	Jul, 2022 (2 months ago)
EP1625847B1	MERCK SHARP DOHME	Medical Use Of A Tetrahydrotriazolo[4,3-A]Pyrazine	Jul, 2022 (2 months ago)
EP1625847A1	MERCK SHARP DOHME	Medical Use Of A Tetrahydrotriazolo[4,3-A]Pyrazine	Jul, 2022 (2 months ago)
EP2292232A1	MERCK SHARP DOHME	Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines For Use In The Treatment Of Diabetes Type Ii	Jul, 2022 (2 months ago)

Drugs and Companies using SITAGLIPTIN PHOSPHATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 25MG BASE	TABLET;ORAL	Prescription
EQ 50MG BASE	TABLET;ORAL	Prescription
EQ 100MG BASE	TABLET;ORAL	Prescription

37. Drug name - JUVISYNC

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6699871	MERCK SHARP DOHME	Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes	Jul, 2022 (2 months ago)
CN1524082A	MERCK SHARP DOHME	As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prophylaxis Of Diabetes Of -Amino Tetrahydro-Imidazo (1, 2-A) Pyrazines And Triazolo [4, 2,3-A) Pyrazine	Jul, 2022 (2 months ago)
CN1290848C	MERCK SHARP DOHME	As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prophylaxis Of Diabetes Of -Amino Tetrahydro-Imidazo (1, 2-A) Pyrazines And Triazolo [4, 2,3-A) Pyrazine	Jul, 2022 (2 months ago)
IN200400026P4	MERCK SHARP DOHME	Beta-Amino Heterocyclic Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes	Jul, 2022 (2 months ago)
IN209816B	MERCK SHARP DOHME	Beta-Amino Heterocyclic Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes	Jul, 2022 (2 months ago)
EP2292232B1	MERCK SHARP DOHME	Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines For Use In The Treatment Of Diabetes Type Ii	Jul, 2022 (2 months ago)
EP1625847B1	MERCK SHARP DOHME	Medical Use Of A Tetrahydrotriazolo[4,3-A]Pyrazine	Jul, 2022 (2 months ago)
EP1625847A1	MERCK SHARP DOHME	Medical Use Of A Tetrahydrotriazolo[4,3-A]Pyrazine	Jul, 2022 (2 months ago)
EP2292232A1	MERCK SHARP DOHME	Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines For Use In The Treatment Of Diabetes Type Ii	Jul, 2022 (2 months ago)

Drugs and Companies using SIMVASTATIN; SITAGLIPTIN PHOSPHATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
10MG;EQ 50MG BASE	TABLET;ORAL	Discontinued
10MG;EQ 100MG BASE	TABLET;ORAL	Discontinued
20MG;EQ 50MG BASE	TABLET;ORAL	Discontinued
20MG;EQ 100MG BASE	TABLET;ORAL	Discontinued
40MG;EQ 50MG BASE	TABLET;ORAL	Discontinued
40MG;EQ 100MG BASE	TABLET;ORAL	Discontinued

38. Drug name - LEQVIO

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9074213	NOVARTIS	Compositions and methods for inhibiting expression of a target gene	Mar, 2022 (6 months ago)
US8546143	NOVARTIS	Compositions and methods for inhibiting expression of a target gene	Apr, 2022 (5 months ago)
IN203882B	NOVARTIS	Method For Inhibiting The Expression Of A Targe Gene	Jan, 2022 (8 months ago)
IN213846B	NOVARTIS	Method For Inhibiting The Expression Of A Target Gene	Jan, 2022 (8 months ago)
IN200300572P3	NOVARTIS	Method For Inhibiting The Expression Of A Target Gene	Jan, 2022 (8 months ago)
IN200300537P3	NOVARTIS	Method For Inhibiting The Expression Of A Target Gene	Jan, 2022 (8 months ago)
EP1352061B1	NOVARTIS	Method For Inhibiting The Expression Of A Target Gene	Jan, 2022 (8 months ago)
EP1352061B9	NOVARTIS	Method For Inhibiting The Expression Of A Target Gene	Jan, 2022 (8 months ago)
EP1352061A2	NOVARTIS	Method For Inhibiting The Expression Of A Target Gene	Jan, 2022 (8 months ago)
EP2213736A3	NOVARTIS	Method For Inhibiting The Expression Of A Target Gene And Medicine For Treating A Tumour Illness	Jan, 2022 (8 months ago)
EP2213736B1	NOVARTIS	Method For Inhibiting The Expression Of A Target Gene And Medicine For Treating A Tumour Illness	Jan, 2022 (8 months ago)
EP2213736A2	NOVARTIS	Method For Inhibiting The Expression Of A Target Gene And Medicine For Treating A Tumour Illness	Jan, 2022 (8 months ago)

Drugs and Companies using INCLISIRAN SODIUM ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
EQ 284MG BASE/1.5ML (EQ 189MG BASE/ML)	SOLUTION;SUBCUTANEOUS	Prescription

39. Drug name - LEXAPRO

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6916941	ALLERGAN	Crystalline composition containing escitalopram	Aug, 2022 (a month ago)
CN1311819C	ALLERGAN	Crystalline Composition Containing Escitalopram	Jul, 2022 (2 months ago)
CN1536997A	ALLERGAN	Crystalline Composition Containing Escitalopram	Jul, 2022 (2 months ago)
IN227935B	ALLERGAN	A Method For Manufacture Of Crystalline Particles Of Escitalpram Oxalate	Jul, 2022 (2 months ago)
IN200400405P4	ALLERGAN	Crystalline Composition Containing Escitalopram	Jul, 2022 (2 months ago)
EP1414435B1	ALLERGAN	Crystalline Composition Containing Escitalopram	Jul, 2022 (2 months ago)
EP1414435A1	ALLERGAN	Crystalline Composition Containing Escitalopram	Jul, 2022 (2 months ago)

Drugs and Companies using ESCITALOPRAM OXALATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 5MG BASE	TABLET;ORAL	Prescription
EQ 10MG BASE	TABLET;ORAL	Prescription
EQ 20MG BASE	TABLET;ORAL	Prescription

40. Drug name - LEXISCAN

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6403567	ASTELLAS	N-pyrazole A2A adenosine receptor agonists	Apr, 2022 (5 months ago)

Drugs and Companies using REGADENOSON ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
0.4MG/5ML (0.08MG/ML)	SOLUTION;INTRAVENOUS	Prescription

41. Drug name - LUPKYNIS

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7332472	AURINIA	Cyclosporine analogue mixtures and their use as immunomodulating agents	Oct, 2022 (13 days from now)
CN100344648C	AURINIA	Cyclosporine Analogue Mixtures And Their Use In Preparation Of Immunomodulator	Oct, 2022 (13 days from now)
CN1571795A	AURINIA	Synthesis Of Cyclosporin Analogs	Oct, 2022 (13 days from now)
CN100334106C	AURINIA	Synthesis Of Cyclosporin Analogs	Oct, 2022 (13 days from now)
CN1274294C	AURINIA	Cyclosporin Analog Microemulsion Preconcentrates	Oct, 2022 (13 days from now)
CN1571657A	AURINIA	Novel Cyclosporin Analog Microemulsion Preconcentrates	Oct, 2022 (13 days from now)
CN1571794A	AURINIA	Cyclosporine Analogue Mixtures And Their Use As Immunomodulating Agents	Oct, 2022 (13 days from now)
CN100497748C	AURINIA	Polishing Component And The Conductive Layer To Perform Electrolytic Polishing Method	Nov, 2022 (a month from now)
CN1585835A	AURINIA	Polishing Assembly And The Conductive Layer Is Subjected To Electrolytic Polishing Method	Nov, 2022 (a month from now)
IN200400693P1	AURINIA	Synthesis Of Cyclosporin Analogs	Oct, 2022 (13 days from now)
IN201105103P1	AURINIA	Method Of Producing An E-Isomer And A Z-Isomer	Oct, 2022 (13 days from now)
IN256418B	AURINIA	Synthesis Of Cyclosporin Analogs	Oct, 2022 (13 days from now)
IN304347B	AURINIA	Method Of Producing An E-Isomer And A Z-Isomer	Oct, 2022 (13 days from now)
EP1436322B1	AURINIA	Cyclosporine Analogue Mixtures And Their Use As Immunomodulating Agents	Oct, 2022 (13 days from now)
EP1714977B1	AURINIA	Synthesis Of Cyclosporin Analogs	Oct, 2022 (13 days from now)
EP1436321B9	AURINIA	Synthesis Of Cyclosporin Analogs	Oct, 2022 (13 days from now)
EP1714977A2	AURINIA	Synthesis Of Cyclosporin Analogs	Oct, 2022 (13 days from now)
EP1436321B1	AURINIA	Synthesis Of Cyclosporin Analogs	Oct, 2022 (13 days from now)
EP1435910B1	AURINIA	Novel Cyclosporin Analog Microemulsion Preconcentrates	Oct, 2022 (13 days from now)
EP1435910A1	AURINIA	Novel Cyclosporin Analog Microemulsion Preconcentrates	Oct, 2022 (13 days from now)
EP1436322A2	AURINIA	Cyclosporine Analogue Mixtures And Their Use As Immunomodulating Agents	Oct, 2022 (13 days from now)
EP1436321A2	AURINIA	Synthesis Of Cyclosporin Analogs	Oct, 2022 (13 days from now)
EP1714977A3	AURINIA	Synthesis Of Cyclosporin Analogs	Oct, 2022 (13 days from now)
EP1435910B9	AURINIA	Novel Cyclosporin Analog Microemulsion Preconcentrates	Oct, 2022 (13 days from now)

Drugs and Companies using VOCLOSPORIN ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
7.9MG	CAPSULE;ORAL	Prescription

42. Drug name - LUSEDRA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6204257	EISAI INC	Water soluble prodrugs of hindered alcohols	Jul, 2022 (3 months ago)

Drugs and Companies using FOSPROPOFOL DISODIUM ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
1050MG/30ML (35MG/ML)	SOLUTION;INTRAVENOUS	Discontinued

43. Drug name - LYNPARZA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7151102	ASTRAZENECA	Phthalazinone derivatives	Apr, 2022 (5 months ago)

Drugs and Companies using OLAPARIB ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
50MG	CAPSULE;ORAL	Discontinued

44. Drug name - MACRILEN

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6861409	NOVO	Growth hormone secretagogues	Aug, 2022 (2 months ago)

Drugs and Companies using MACIMORELIN ACETATE ingredient

Treatment: NA

Dosage: FOR SOLUTION;ORAL

Strength	Dosage	Availability
EQ 60MG BASE/POUCH	FOR SOLUTION;ORAL	Prescription

45. Drug name - MICARDIS

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8003679	BOEHRINGER INGELHEIM	Use of inhibitors of the renin-angiotensin system	Oct, 2022 (2 days from now)

Drugs and Companies using TELMISARTAN ingredient

Treatment: Treatment or prevention of stroke

Dosage: TABLET;ORAL

Strength	Dosage	Availability
20MG	TABLET;ORAL	Prescription
40MG	TABLET;ORAL	Prescription
80MG	TABLET;ORAL	Prescription

46. Drug name - MOVANTIK

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7662365	REDHILL	Polymer conjugates of opioid antagonists	Oct, 2022 (14 days from now)
EP1436012A2	REDHILL	Polymer Conjugates Of Opioid Antagonists	Oct, 2022 (14 days from now)
EP2939696A1	REDHILL	Polymer Conjugates Of Opioid Antagonists	Oct, 2022 (14 days from now)
EP1436012B1	REDHILL	Polymer Conjugates Of Opioid Antagonists	Oct, 2022 (14 days from now)
EP2939696B1	REDHILL	Polymer Conjugates Of Opioid Antagonists	Oct, 2022 (14 days from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8617530	REDHILL	Polymer conjugates of opioid antagonists	Oct, 2022 (14 days from now)

Drugs and Companies using NALOXEGOL OXALATE ingredient

Treatment: Treatment of opioid-induced constipation

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 12.5MG BASE	TABLET;ORAL	Prescription
EQ 25MG BASE	TABLET;ORAL	Prescription

47. Drug name - MYRBETRIQ

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6346532	APGDI	Amide derivatives or salts thereof	Mar, 2022 (6 months ago)

Drugs and Companies using MIRABEGRON ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
25MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
50MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

48. Drug name - MYRBETRIQ GRANULES

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6346532	APGDI	Amide derivatives or salts thereof	Mar, 2022 (6 months ago)

Drugs and Companies using MIRABEGRON ingredient

Treatment: NA

Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
8MG/ML	FOR SUSPENSION, EXTENDED RELEASE;ORAL	Prescription

49. Drug name - NEURONTIN

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7256216 (Pediatric)	VIATRIS	Liquid pharmaceutical compositions	Nov, 2022 (a month from now)

Drugs and Companies using GABAPENTIN ingredient

Treatment: NA

Dosage: SOLUTION;ORAL

Strength	Dosage	Availability
250MG/5ML	SOLUTION;ORAL	Prescription

50. Drug name - NUCYNTA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE39593	COLLEGIUM PHARM INC	1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects	Aug, 2022 (a month ago)

Drugs and Companies using TAPENTADOL HYDROCHLORIDE ingredient

Treatment: NA

Dosage: SOLUTION;ORAL

Strength	Dosage	Availability
EQ 20MG BASE/ML	SOLUTION;ORAL	Discontinued

51. Drug name - NUCYNTA ER

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE39593	COLLEGIUM PHARM INC	1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects	Aug, 2022 (a month ago)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11007156	COLLEGIUM PHARM INC	Prolonged release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol	Oct, 2022 (18 days from now)

Drugs and Companies using TAPENTADOL HYDROCHLORIDE ingredient

Treatment: Relief of moderate to severe chronic pain; management of neuropathic pain associated with diabetic peripheral neuropathy

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
EQ 50MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 100MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 150MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 200MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 250MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription

52. Drug name - OCALIVA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7138390	INTERCEPT PHARMS INC	Steroids as agonists for FXR	Nov, 2022 (a month from now)
EP1392714A1	INTERCEPT PHARMS INC	Steroids As Agonists For Fxr	Feb, 2022 (7 months ago)
EP1392714B1	INTERCEPT PHARMS INC	Steroids As Agonists For Fxr	Feb, 2022 (7 months ago)

Drugs and Companies using OBETICHOLIC ACID ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
5MG	TABLET;ORAL	Prescription
10MG	TABLET;ORAL	Prescription

53. Drug name - OFORTA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7148207	SANOFI AVENTIS US	Oral fludara of high-purity formulation with quick release of active ingredient	Dec, 2022 (2 months from now)

Drugs and Companies using FLUDARABINE PHOSPHATE ingredient

Treatment: Treatment of patients with b-cell chronic lymphocytic leukemia (cll)

Dosage: TABLET;ORAL

Strength	Dosage	Availability
10MG	TABLET;ORAL	Discontinued

54. Drug name - OSPHENA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9566252	DUCHESNAY	Method for the alleviation of dyspareunia in women	Nov, 2022 (29 days from now)

Drugs and Companies using OSPEMIFENE ingredient

Treatment: Treatment of dyspareunia associated with menopause

Dosage: TABLET;ORAL

Strength	Dosage	Availability
60MG	TABLET;ORAL	Prescription

55. Drug name - PEPAXTO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6992207	ONCOPEPTIDES AB	Melphalan derivatives and their use as cancer chemotherapeutic drugs	Jun, 2022 (3 months ago)

Drugs and Companies using MELPHALAN FLUFENAMIDE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
EQ 20MG BASE/VIAL	POWDER;INTRAVENOUS	Discontinued

56. Drug name - PRISTIQ

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6673838	PF PRISM CV	Succinate salt of O-desmethyl-venlafaxine	Mar, 2022 (7 months ago)
CN1501909A	PF PRISM CV	A New O-Demethyl-Venlafaxine Succinate	Feb, 2022 (7 months ago)
CN100567253C	PF PRISM CV	O-Desmethyl-Venlafaxine Succinate	Feb, 2022 (7 months ago)
IN200301015P2	PF PRISM CV	Novel Succinate Salt Of O-Desmethyl-Venlafaxine	Feb, 2022 (7 months ago)
IN201649B	PF PRISM CV	Novel Succinate Salt Of O-Desmethyl- Venlafaxine	Feb, 2022 (7 months ago)
EP1360169B2	PF PRISM CV	Succinate Salt Of O-Desmethyl-Venlafaxine	Feb, 2022 (7 months ago)
EP1360169B1	PF PRISM CV	Succinate Salt Of O-Desmethyl-Venlafaxine	Feb, 2022 (7 months ago)
EP1360169A2	PF PRISM CV	Succinate Salt Of O-Desmethyl-Venlafaxine	Feb, 2022 (7 months ago)

Drugs and Companies using DESVENLAFAXINE SUCCINATE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
EQ 25MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 50MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 100MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription

57. Drug name - PROMACTA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7160870	NOVARTIS	Thrombopoietin mimetics	Nov, 2022 (a month from now)

Drugs and Companies using ELTROMBOPAG OLAMINE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 12.5MG ACID	TABLET;ORAL	Prescription
EQ 25MG ACID	TABLET;ORAL	Prescription
EQ 50MG ACID	TABLET;ORAL	Prescription
EQ 75MG ACID	TABLET;ORAL	Prescription
EQ 100MG ACID	TABLET;ORAL	Discontinued

58. Drug name - PROMACTA KIT

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7160870	NOVARTIS	Thrombopoietin mimetics	Nov, 2022 (a month from now)

Drugs and Companies using ELTROMBOPAG OLAMINE ingredient

Treatment: NA

Dosage: FOR SUSPENSION;ORAL

Strength	Dosage	Availability
EQ 12.5MG ACID/PACKET	FOR SUSPENSION;ORAL	Prescription
EQ 25MG ACID/PACKET	FOR SUSPENSION;ORAL	Prescription

59. Drug name - RYANODEX

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8110225	EAGLE PHARMS	Treatment using dantrolene	Dec, 2022 (2 months from now)
US8604072	EAGLE PHARMS	Treatment using dantrolene	Dec, 2022 (2 months from now)

Drugs and Companies using DANTROLENE SODIUM ingredient

Treatment: NA

Dosage: FOR SUSPENSION;INTRAVENOUS

Strength	Dosage	Availability
250MG/VIAL	FOR SUSPENSION;INTRAVENOUS	Prescription

60. Drug name - RYDAPT

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8222244	NOVARTIS	Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity	Oct, 2022 (25 days from now)

Drugs and Companies using MIDOSTAURIN ingredient

Treatment: Treatment of adult patients with newly diagnosed acute myeloid leukemia (aml) who are flt3 mutation-positive, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
25MG	CAPSULE;ORAL	Prescription

61. Drug name - SAXENDA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6268343	NOVO	Derivatives of GLP-1 analogs	Aug, 2022 (a month ago)
EP944648A1	NOVO	Glp-1 Derivatives	Aug, 2022 (a month ago)
EP944648B1	NOVO	Glp-1 Derivatives	Aug, 2022 (a month ago)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8846618 (Pediatric)	NOVO	Stable formulation of modified GLP-1	Dec, 2022 (2 months from now)

Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
18MG/3ML (6MG/ML)	SOLUTION;SUBCUTANEOUS	Prescription

62. Drug name - SELZENTRY

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7368460	VIIV HLTHCARE	Tropane derivatives useful in therapy	Nov, 2022 (a month from now)

Drugs and Companies using MARAVIROC ingredient

Treatment: Method of treating patients infected with ccr5-tropic hiv-1

Dosage: TABLET;ORAL

Strength	Dosage	Availability
25MG	TABLET;ORAL	Prescription
75MG	TABLET;ORAL	Prescription
150MG	TABLET;ORAL	Prescription
300MG	TABLET;ORAL	Prescription

63. Drug name - SINGULAIR

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8007830	MERCK	Granule formation	Oct, 2022 (20 days from now)

Drugs and Companies using MONTELUKAST SODIUM ingredient

Treatment: NA

Dosage: GRANULE;ORAL

Strength	Dosage	Availability
EQ 4MG BASE/PACKET	GRANULE;ORAL	Prescription

64. Drug name - STEGLUJAN

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6699871	MERCK SHARP DOHME	Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes	Jul, 2022 (2 months ago)
CN1524082A	MERCK SHARP DOHME	As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prophylaxis Of Diabetes Of -Amino Tetrahydro-Imidazo (1, 2-A) Pyrazines And Triazolo [4, 2,3-A) Pyrazine	Jul, 2022 (2 months ago)
CN1290848C	MERCK SHARP DOHME	As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prophylaxis Of Diabetes Of -Amino Tetrahydro-Imidazo (1, 2-A) Pyrazines And Triazolo [4, 2,3-A) Pyrazine	Jul, 2022 (2 months ago)
IN200400026P4	MERCK SHARP DOHME	Beta-Amino Heterocyclic Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes	Jul, 2022 (2 months ago)
IN209816B	MERCK SHARP DOHME	Beta-Amino Heterocyclic Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes	Jul, 2022 (2 months ago)
EP2292232B1	MERCK SHARP DOHME	Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines For Use In The Treatment Of Diabetes Type Ii	Jul, 2022 (2 months ago)
EP1625847B1	MERCK SHARP DOHME	Medical Use Of A Tetrahydrotriazolo[4,3-A]Pyrazine	Jul, 2022 (2 months ago)
EP1625847A1	MERCK SHARP DOHME	Medical Use Of A Tetrahydrotriazolo[4,3-A]Pyrazine	Jul, 2022 (2 months ago)
EP2292232A1	MERCK SHARP DOHME	Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines For Use In The Treatment Of Diabetes Type Ii	Jul, 2022 (2 months ago)

Drugs and Companies using ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
5MG;EQ 100MG BASE	TABLET;ORAL	Prescription
15MG;EQ 100MG BASE	TABLET;ORAL	Prescription

65. Drug name - STIVARGA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7351834	BAYER HLTHCARE	ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors	Jun, 2022 (3 months ago)
EP1379507B1	BAYER HLTHCARE	Heteroaryl Ureas Containing Nitrogen Hetero-Atoms As P38 Kinase Inhibitors	Apr, 2022 (5 months ago)
EP1379507A1	BAYER HLTHCARE	Heteroaryl Ureas Containing Nitrogen Hetero-Atoms As P38 Kinase Inhibitors	Apr, 2022 (5 months ago)

Drugs and Companies using REGORAFENIB ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
40MG	TABLET;ORAL	Prescription

66. Drug name - SUBOXONE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10285910	INDIVIOR INC	Sublingual and buccal film compositions	Oct, 2022 (7 days from now)

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: FILM;BUCCAL, SUBLINGUAL

Strength	Dosage	Availability
EQ 2MG BASE;EQ 0.5MG BASE	FILM;BUCCAL, SUBLINGUAL	Prescription
EQ 4MG BASE;EQ 1MG BASE	FILM;BUCCAL, SUBLINGUAL	Prescription
EQ 8MG BASE;EQ 2MG BASE	FILM;BUCCAL, SUBLINGUAL	Prescription
EQ 12MG BASE;EQ 3MG BASE	FILM;BUCCAL, SUBLINGUAL	Prescription

67. Drug name - SUMAVEL DOSEPRO

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8343130	ENDO VENTURES LTD	Needleless injector	Oct, 2022 (14 days from now)
US8491524	ENDO VENTURES LTD	Needleless injector drug capsule and a method for filling thereof	Nov, 2022 (a month from now)
US8241244	ENDO VENTURES LTD	Needleless injector drug capsule and a method for filling thereof	Nov, 2022 (a month from now)

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Treatment: NA

Dosage: INJECTABLE;SUBCUTANEOUS

Strength	Dosage	Availability
EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	INJECTABLE;SUBCUTANEOUS	Discontinued
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	INJECTABLE;SUBCUTANEOUS	Discontinued

68. Drug name - TEFLARO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6417175	ALLERGAN	Phosphonocephem derivatives, process for the preparation of the same, and use thereof	Apr, 2022 (5 months ago)

Drugs and Companies using CEFTAROLINE FOSAMIL ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
400MG/VIAL	POWDER;INTRAVENOUS	Prescription
600MG/VIAL	POWDER;INTRAVENOUS	Prescription

69. Drug name - TOBI PODHALER

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8715623	MYLAN SPECIALITY LP	Pulmonary delivery of aminoglycoside	Dec, 2022 (2 months from now)
US9421166	MYLAN SPECIALITY LP	Pulmonary delivery of aminoglycoside	Dec, 2022 (2 months from now)
US7368102	MYLAN SPECIALITY LP	Pulmonary delivery of aminoglycosides	Dec, 2022 (2 months from now)

Drugs and Companies using TOBRAMYCIN ingredient

Treatment: Treatment of cystic fibrosis patients with pseudomonas aeruginosa

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
28MG	POWDER;INHALATION	Prescription

70. Drug name - TOVIAZ

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6858650	PFIZER	Stable salts of novel derivatives of 3,3-diphenylpropylamines	Jul, 2022 (3 months ago)

Drugs and Companies using FESOTERODINE FUMARATE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
4MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
8MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

71. Drug name - TRI-LUMA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8247395	GALDERMA LABS LP	Topical skin care composition	Oct, 2022 (21 days from now)
US8653053	GALDERMA LABS LP	Topical skin care composition	Oct, 2022 (21 days from now)

Drugs and Companies using FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN ingredient

Treatment: NA

Dosage: CREAM;TOPICAL

Strength	Dosage	Availability
0.01%;4%;0.05%	CREAM;TOPICAL	Prescription

72. Drug name - TRULANCE

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7799897	SALIX	Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis	Jun, 2022 (3 months ago)
CN103641892B	SALIX	Guanylate Cyclase Receptor Agonist For Treating Tissue Inflammation And Cancer	Mar, 2022 (6 months ago)
CN102643333B	SALIX	Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis	Mar, 2022 (6 months ago)
CN102643333A	SALIX	Guanylate Cyclase Receptor Stimulant For Treating Tissue Inflammation And Canceration	Mar, 2022 (6 months ago)
CN103641892A	SALIX	For Treating Tissue Inflammation And Cancer Of Guanylate Cyclase Receptor Agonist	Mar, 2022 (6 months ago)
EP2103624B1	SALIX	Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis	Mar, 2022 (6 months ago)
EP2301952A2	SALIX	Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis	Mar, 2022 (6 months ago)
EP2944648B1	SALIX	Guanylate Cyclase Receptor Agonists For The Treatment Of Organ Inflammation	Mar, 2022 (6 months ago)
EP2301952B1	SALIX	Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis	Mar, 2022 (6 months ago)
EP2103624A1	SALIX	Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis	Mar, 2022 (6 months ago)
EP2944648A1	SALIX	Guanylate Cyclase Receptor Agonists For The Treatment Of Organ Inflammation	Mar, 2022 (6 months ago)
EP2301952A3	SALIX	Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis	Mar, 2022 (6 months ago)
EP1379224B1	SALIX	Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis	Mar, 2022 (6 months ago)
EP1379224A4	SALIX	Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis	Mar, 2022 (6 months ago)
EP1379224A1	SALIX	Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis	Mar, 2022 (6 months ago)
EP1379224B2	SALIX	Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis	Mar, 2022 (6 months ago)

Drugs and Companies using PLECANATIDE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
3MG	TABLET;ORAL	Prescription

73. Drug name - VARUBI

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8796299	TERSERA	NK1 antagonists	Dec, 2022 (2 months from now)

Drugs and Companies using ROLAPITANT HYDROCHLORIDE ingredient

Treatment: Prevention of delayed nausea and vomiting associated with emetogenic cancer chemotherapy

Dosage: EMULSION;INTRAVENOUS

Strength	Dosage	Availability
EQ 166.5MG BASE/92.5ML (EQ 1.8MG BASE/ML)	EMULSION;INTRAVENOUS	Discontinued

74. Drug name - VELCADE

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6958319	TAKEDA PHARMS USA	Formulation of boronic acid compounds	Jan, 2022 (8 months ago)
US6713446	TAKEDA PHARMS USA	Formulation of boronic acid compounds	Jan, 2022 (8 months ago)
EP2251344A1	TAKEDA PHARMS USA	Formulation Of Boronic Acid Compounds	Jan, 2022 (8 months ago)
EP1355910A1	TAKEDA PHARMS USA	Formulation Of Boronic Acid Compounds	Jan, 2022 (8 months ago)
EP2251344B1	TAKEDA PHARMS USA	Formulation Of Boronic Acid Compounds	Jan, 2022 (8 months ago)
EP1355910B1	TAKEDA PHARMS USA	Formulation Of Boronic Acid Compounds	Jan, 2022 (8 months ago)
EP3078667B1	TAKEDA PHARMS USA	Formulation Of Boronic Acid Compounds	Jan, 2022 (8 months ago)
EP3078667A1	TAKEDA PHARMS USA	Formulation Of Boronic Acid Compounds	Jan, 2022 (8 months ago)

Drugs and Companies using BORTEZOMIB ingredient

Treatment: NA

Dosage: INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

Strength	Dosage	Availability
3.5MG/VIAL	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS	Prescription

75. Drug name - VEREGEN

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10434059	ANI PHARMS	Medicament for the treatment of viral skin and tumour diseases	Nov, 2022 (a month from now)

Drugs and Companies using SINECATECHINS ingredient

Treatment: Treatment of genital warts

Dosage: OINTMENT;TOPICAL

Strength	Dosage	Availability
15%	OINTMENT;TOPICAL	Prescription

76. Drug name - VICTOZA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6268343	NOVO NORDISK INC	Derivatives of GLP-1 analogs	Aug, 2022 (a month ago)
EP944648A1	NOVO NORDISK INC	Glp-1 Derivatives	Aug, 2022 (a month ago)
EP944648B1	NOVO NORDISK INC	Glp-1 Derivatives	Aug, 2022 (a month ago)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8846618 (Pediatric)	NOVO NORDISK INC	Stable formulation of modified GLP-1	Dec, 2022 (2 months from now)

Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
18MG/3ML (6MG/ML)	SOLUTION;SUBCUTANEOUS	Prescription

77. Drug name - VIIBRYD

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7834020	ALLERGAN	Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride	Jun, 2022 (3 months ago)
US8673921	ALLERGAN	Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride	Jun, 2022 (3 months ago)
CN100384841C	ALLERGAN	1 - [4 - (5-Cyanoindol-3-Group) Butyl] - 4 - (2-Carbamoyl-Benzofuran-5-Yl) - Piperazine Hydrochloride Polymorph	Jun, 2022 (3 months ago)
CN101139345A	ALLERGAN	Polymorphic Forms Of 1-4-(5-Cyanoindol-3-Group) Butyl-4-(2-Carbamoylbenzofuran-5-Group) Piperazine Hydrochloride	Jun, 2022 (3 months ago)
CN1516699A	ALLERGAN	1 - [4 - (5-Cyanoindol-3-Group) Butyl] - 4 - (2-Carbamoyl-Benzofuran-5-Yl) - Piperazine Hydrochloride Polymorph	Jun, 2022 (3 months ago)
CN101139345B	ALLERGAN	1 - [4 - (5-Indole-3-Yl) Butyl] - 4 - (2-Carbamoyl-Benzofuran-5-Yl) - Piperazine Hydrochloride Polymorph	Jun, 2022 (3 months ago)
EP1397357B1	ALLERGAN	Polymorphic Forms Of 1-[4-(5-Cyanoindol-3-Yl)Butyl]-4-(2-Carbamoylbenzofuran-5-Yl)Piperazine Hydrochloride	Jun, 2022 (3 months ago)
EP1397357A2	ALLERGAN	Polymorphic Forms Of 1-[4-(5-Cyanoindol-3-Yl)Butyl]-4-(2-Carbamoylbenzofuran-5-Yl)Piperazine Hydrochloride	Jun, 2022 (3 months ago)
EP1397357B9	ALLERGAN	Polymorphic Forms Of 1-[4-(5-Cyanoindol-3-Yl)Butyl]-4-(2-Carbamoylbenzofuran-5-Yl)Piperazine Hydrochloride	Jun, 2022 (3 months ago)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8673921 (Pediatric)	ALLERGAN	Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride	Dec, 2022 (2 months from now)
US7834020 (Pediatric)	ALLERGAN	Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride	Dec, 2022 (2 months from now)
US8193195 (Pediatric)	ALLERGAN	Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride	Dec, 2022 (2 months from now)
US8236804 (Pediatric)	ALLERGAN	Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride	Dec, 2022 (2 months from now)

Drugs and Companies using VILAZODONE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
10MG	TABLET;ORAL	Prescription
20MG	TABLET;ORAL	Prescription
40MG	TABLET;ORAL	Prescription

78. Drug name - VIMPAT

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE38551	UCB INC	Anticonvulsant enantiomeric amino acid derivatives	Mar, 2022 (6 months ago)
EP888289A1	UCB INC	Anticonvulsant Enantiomeric Amino Acid Derivatives	Mar, 2022 (6 months ago)
EP888289B1	UCB INC	Anticonvulsant Enantiomeric Amino Acid Derivatives	Mar, 2022 (6 months ago)

Drugs and Companies using LACOSAMIDE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
200MG/20ML (10MG/ML)	SOLUTION;INTRAVENOUS	Prescription

79. Drug name - WELCHOL

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7229613 (Pediatric)	DAIICHI SANKYO	Method for lowering serum glucose	Oct, 2022 (13 days from now)

Drugs and Companies using COLESEVELAM HYDROCHLORIDE ingredient

Treatment: NA

Dosage: FOR SUSPENSION;ORAL

Strength	Dosage	Availability
1.875GM/PACKET	FOR SUSPENSION;ORAL	Discontinued
3.75GM/PACKET	FOR SUSPENSION;ORAL	Prescription

80. Drug name - XERESE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7223387	BAUSCH	Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester	Nov, 2022 (a month from now)

Drugs and Companies using ACYCLOVIR; HYDROCORTISONE ingredient

Treatment: New combination product for the early treatment of recurrent herpes labialis (cold sores) to reduce the likelihood of ulcerative cold sores and to shorten the lesion healing time in adults and adolescents (12 years of age and older); combination product for the early treatment of recurrent herpes labialis (cold sores) to reduce the likelihood of ulcerative cold sores and to shorten the lesion healing time in adults and children (6 years of age and older)

Dosage: CREAM;TOPICAL

Strength	Dosage	Availability
5%;1%	CREAM;TOPICAL	Prescription

81. Drug name - XOFIGO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6635234	BAYER HLTHCARE	Preparation and use of radium-223 to target calcified tissues for pain palliation, bone cancer therapy, and bone surface conditioning	Nov, 2022 (a month from now)

Drugs and Companies using RADIUM RA-223 DICHLORIDE ingredient

Treatment: Therapeutic treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
162mCi/6ML (27mCi/ML)	SOLUTION;INTRAVENOUS	Prescription

82. Drug name - XYREM

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8731963	JAZZ PHARMS	Sensitive drug distribution system and method	Dec, 2022 (2 months from now)

Drugs and Companies using SODIUM OXYBATE ingredient

Treatment: Method of treating a patient with a prescription drug using a computer database in a computer system for distribution

Dosage: SOLUTION;ORAL

Strength	Dosage	Availability
0.5GM/ML	SOLUTION;ORAL	Prescription

83. Drug name - XYWAV

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8731963	JAZZ	Sensitive drug distribution system and method	Dec, 2022 (2 months from now)

Drugs and Companies using CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE ingredient

Treatment: Method of treating a patient with a prescription drug using a computer database in a computer system for distribution

Dosage: SOLUTION;ORAL

Strength	Dosage	Availability
0.234GM/ML;0.096GM/ML;0.13GM/ML;0.04GM/ML	SOLUTION;ORAL	Prescription

84. Drug name - ZIOPTAN

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US5886035	AKORN	Difluoroprostaglandin derivatives and their use	Dec, 2022 (2 months from now)
EP850926A3	AKORN	Difluoroprostaglandin Derivatives And Their Use	Dec, 2022 (2 months from now)
EP850926A2	AKORN	Difluoroprostaglandin Derivatives And Their Use	Dec, 2022 (2 months from now)
EP850926B1	AKORN	Difluoroprostaglandin Derivatives And Their Use	Dec, 2022 (2 months from now)

Drugs and Companies using TAFLUPROST ingredient

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

Strength	Dosage	Availability
0.0015%	SOLUTION/DROPS;OPHTHALMIC	Prescription

Pharsight

Drug Patents Expiring in 2022

1. Drug name - ABILIFY

2. Drug name - ABILIFY MAINTENA KIT

3. Drug name - ABILIFY MYCITE KIT

4. Drug name - ADDYI

5. Drug name - AMITIZA

6. Drug name - AMLODIPINE BESYLATE

7. Drug name - ANJESO

8. Drug name - AVANDAMET

9. Drug name - BANZEL

10. Drug name - BEYAZ

11. Drug name - BYDUREON

12. Drug name - BYDUREON BCISE

13. Drug name - BYLVAY

14. Drug name - CAPRELSA

15. Drug name - CERDELGA

16. Drug name - CHANTIX

17. Drug name - COMBIGAN

18. Drug name - DORYX

19. Drug name - DUTREBIS

20. Drug name - EPIDIOLEX

21. Drug name - EPIDUO

22. Drug name - EPIDUO FORTE

23. Drug name - FOLOTYN

24. Drug name - FUSILEV

25. Drug name - FYCOMPA

26. Drug name - GIVLAARI

27. Drug name - GRALISE

28. Drug name - HALFLYTELY

29. Drug name - HETLIOZ

30. Drug name - HETLIOZ LQ

31. Drug name - HORIZANT

32. Drug name - INBRIJA

33. Drug name - ISENTRESS

34. Drug name - JANUMET

35. Drug name - JANUMET XR

36. Drug name - JANUVIA

37. Drug name - JUVISYNC

38. Drug name - LEQVIO

39. Drug name - LEXAPRO

40. Drug name - LEXISCAN

41. Drug name - LUPKYNIS

42. Drug name - LUSEDRA

43. Drug name - LYNPARZA

44. Drug name - MACRILEN

45. Drug name - MICARDIS

46. Drug name - MOVANTIK

47. Drug name - MYRBETRIQ

48. Drug name - MYRBETRIQ GRANULES

49. Drug name - NEURONTIN

50. Drug name - NUCYNTA

51. Drug name - NUCYNTA ER

52. Drug name - OCALIVA

53. Drug name - OFORTA

54. Drug name - OSPHENA

55. Drug name - PEPAXTO

56. Drug name - PRISTIQ

57. Drug name - PROMACTA

58. Drug name - PROMACTA KIT

59. Drug name - RYANODEX

60. Drug name - RYDAPT

61. Drug name - SAXENDA

62. Drug name - SELZENTRY

63. Drug name - SINGULAIR

64. Drug name - STEGLUJAN

65. Drug name - STIVARGA

66. Drug name - SUBOXONE

67. Drug name - SUMAVEL DOSEPRO

68. Drug name - TEFLARO

69. Drug name - TOBI PODHALER

70. Drug name - TOVIAZ

71. Drug name - TRI-LUMA

72. Drug name - TRULANCE

73. Drug name - VARUBI

74. Drug name - VELCADE

75. Drug name - VEREGEN

76. Drug name - VICTOZA

77. Drug name - VIIBRYD

78. Drug name - VIMPAT

availability in other generic markets.

Click on the highlighted region to filter.